Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 1, 2011, Pages 175-179

  Kvitko, Carlos H ^a   Rigatto, Maria H ^b   Moro, Ana L ^b   Zavascki, Alexandre P ^b,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Colistin; Mortality; Multidrug resistance; P. aeruginosa; Treatment

Indexed keywords

AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION INFECTION; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; DRUG EFFICACY; FEMALE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; CROSS INFECTION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78650335200     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq390     Document Type: Article

References (14)

1. Zavascki AP, Barth AL, Goldani LZ. Nosocomial bloodstream infections due to metallo-b-lactamase-producing Pseudomonas aeruginosa. J Antimicrob Chemother 2008; 61: 1183-5.
2. Zavascki AP, Carvalhaes CG, Picão RC et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010; 8: 71-93.
3. Zavascki AP, Goldani LZ, Li J et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007; 60: 1206-15.
4. Zavascki AP, Li J. Intravenous colistimethate for multidrug-resistant Gram-negative bacteria. Lancet Infect Dis 2008; 8: 403-5.
5. Paul M, Bishara J, Levcovich A et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010; 65: 1019-27.
6. Oliveira MS, Prado GV, Costa SF et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008; 61: 1369-75.
7. Falagas ME, Rafailidis PI, Ioannidou E et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35: 194-9.
8. Elias LS, Konzen D, Krebs JM et al. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010; 65: 2231-7.
9. Rhee JY, Kwon KT, Ki HK et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 2009; 31: 146-50.
10. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
11. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32.
12. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, 2008.
13. Zavascki AP, Goldani LZ, Cao G et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008; 47: 1298-304.
14. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39: 183-90.